Skip to main content

Immix Biopharma, Inc.

IMMX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001873835

No open-market purchases or sales by Immix Biopharma, Inc. insiders were filed in the last 90 days; 109 institutions reported holding it in 13F filings for Q2 2026, worth $579.6M in total; no superinvestor holds it.

Q3 2024 vs. Q2 2024

How the institutions holding Immix Biopharma, Inc. changed between Q2 2024 and Q3 2024.

All holders in Q3 2024All holders in Q2 2024

13F holders of IMMX: Q2 2024 compared with Q3 2024
MeasureQ2 2024Of which not filed for Q3 2024Q3 2024Change
Holders31125−5
Shares4.43M13.5K4.09M−321.9K (−7.3%)
Value$8.77M$26.6K$6.10M−$2.65M (−30.2%)

1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (1)

Institutions that held Immix Biopharma, Inc. at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to IMMX in Q3 2024
InstitutionSharesValue% of portfolio
BlackRock, Inc.14,003$20.9K0.00%

Sold out (6)

Institutions that held Immix Biopharma, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.

Institutions that sold out of IMMX in Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
Renaissance Technologies LLC154,685$306.3K
FNY Investment Advisers, LLC32,500$64.0K
Squarepoint Ops LLC23,010$45.6K
XTX Topco Ltd17,663$35.0K
Corsair Capital Management, L.P.14,217$28.1K
Simplex Trading, LLC449$0

Not filed for Q3 2024 yet (1)

Institutions that held Immix Biopharma, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding IMMX in Q2 2024 that haven't filed for Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
BlackRock Inc.13,455$26.6K